- 作者：Jiang Hua ; Wang Manxia ; Guo Jian ; Li Zhidong
- 刊名：Journal of Traditional Chinese Medicine
- 出版年：2008
- 出版时间：September 2008
- 年：2008
- 卷：28
- 期：3
- 页码：193-197
- 全文大小：113 K
ss=""h4"">Objective
To observe the therapeutic effects of midnight-noon ebb-flow method of selecting acupoints (MNEFMSA) for acute ischemic cerebrovascular diseases (AICD) and its influence on hemorrheology and on the levels of interleukin-6 (IL-6), thromboxane B<sub>2sub> (TXB<sub>2sub>) and 6-keto-prostaglandin F<sub>1αsub> (6-keto-PGF<sub>1αsub>).ss=""h4"">Methods
The 90 cases were randomly divided into 3 groups, each consisting of 30 cases. The drug group was treated mainly by routine medication; in addition to medication, the affected-channel group was treated by acupuncture at points along the course of the affected channel, and the MNEFMSA group was treated by MNEFMSA.
ss=""h4"">Results
The total effective rate of MNEFMSA group, affected-channel group and drug group was 96.67 % , 90 % and 73.33 % respectively. The total effective rate of MNEFMSA group was obviously superior to that of the drug group (P<0.01), and cure rate and marked improvement rate were obviously superior to those of the drug group and the affected-channel group (P<0.05 or P<0.01). After treatment, the three groups all got improvements in the hemorheological indexes, of which MNEFMSA group got marked improvements in the whole blood viscosity and erythrocyte deformability rate, significantly different from the other two groups (P<0.05). At the early stage of treatment and after treatment, the three groups all had IL-6, TXB<sub>2sub> and 6-keto-PGF<sub>1αsub> obviously improved (P<0.05 or P<0.01), of which MNEFMSA group got obvious improvement in 6-keto-PGF<sub>1αsub> and IL-6 ever since the early stage of the treatment (P<0.05).
ss=""h4"">Conclusions
In the treatment of acute ischemic cerebrovascular diseases, MNEFMSA can markedly raise the clinical therapeutic effects by improving the hemorheological indexes, lowering the level of IL-6, and restoring the dynamic equilibrium between TXB<sub>2sub> and 6-keto-PGF1<sub>αsub>, so as to promote the recovery of cerebral nervous function.